Quick Answer
Esperion Therapeutics, Inc. reported Operating Income of $60.27 million for fiscal year 2025.
Esperion Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $60.27M | +10.8% |
| 2024 | $54.40M | +135.0% |
| 2023 | -$155.56M | +13.3% |
| 2022 | -$179.50M | +20.8% |
| 2021 | -$226.73M | -86.8% |
| 2020 | -$121.40M | -30.4% |
| 2019 | -$93.10M | +54.5% |
| 2018 | -$204.59M | -21.1% |
| 2017 | -$168.98M | -121.9% |
| 2016 | -$76.15M | -52.2% |
| 2015 | -$50.04M | -38.1% |
| 2014 | -$36.22M | -59.2% |
| 2013 | -$22.76M | -123.0% |
| 2012 | -$10.20M | -0.4% |
| 2011 | -$10.16M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$9.96M | +37.9% | -240.4% |
| June 30, 2025 | $7.09M | +175.1% | +132.1% |
| March 31, 2025 | -$22.10M | -130.6% | -37.9% |
| September 30, 2024 | -$16.03M | +41.8% | -721.4% |
| June 30, 2024 | $2.58M | +107.0% | -96.4% |
| March 31, 2024 | $72.27M | +248.7% | +362.5% |
| September 30, 2023 | -$27.53M | +33.9% | +25.7% |
| June 30, 2023 | -$37.06M | +29.2% | +23.8% |
- Esperion Therapeutics, Inc. showed an increase of +10.8% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, Esperion Therapeutics, Inc.’s operating income has grown by 693.0% (from -$10.16 million to $60.27 million).
- The most recent figure is from Esperion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: